ArticleThe Journal of clinical endocrinology and metabolism2025
Utility of Salivary Cortisol and Cortisone in the Diagnostics of Adrenal Insufficiency.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Review
- Clinical utility of salivary cortisol for diagnosis and therapeutic monitoring in adrenal insufficiency.Endocrine · 2025Article
- Review
- Utility of Salivary Cortisol and Cortisone in the Diagnostics of Adrenal Insufficiency.The Journal of clinical endocrinology and metabolism · 2025Article
- Research prospect of human salivary cortisol: a bibliometric analysis.Frontiers in psychology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSalivary cortisol (sa-cortisol) and salivary cortisone correlate well with serum cortisol (s-cortisol) but validated reference ranges for healthy individuals are lacking.
objectiveTo establish cutoff levels for sa-cortisol and cortisone following cosyntropin testing and assess their diagnostic utility in adrenal insufficiency (AI).
methodsSteroids in saliva were assayed using liquid chromatography tandem mass spectrometry before and after administration of a 250-µg cosyntropin test in 128 healthy subjects (16 on oral estrogens) and 59 patients with suspected AI, of whom 26 were diagnosed with AI with conventional serum cortisol criteria. The cutoff level for AI was defined as the 2.5th percentile in healthy subjects not receiving estrogens. Performance was evaluated by calculating diagnostic accuracy and analyzing receiver operating characteristic curves.
resultsThe sa-cortisol cutoff 60 minutes after cosyntropin stimulation was 12.6 nmol/L (accuracy 89%, sensitivity 85%, and specificity 90%). Salivary cortisone and the sum of sa-cortisol and cortisone exhibited poorer diagnostic performance than sa-cortisol. The correlation between sa-cortisol and s-cortisol was best described by a model incorporating 2 regression lines (R2 = 0.80). Segmented regression analysis identified a breakpoint at sa-cortisol 9.7 nmol/L and s-cortisol 482 nmol/L, likely corresponding to saturation of cortisol binding globulin. Healthy subjects on oral estrogens demonstrated a linear agreement between s- and sa-cortisol through all measurements. Seventeen healthy subjects repeated the test, with similar outcomes, but reproducibility in terms of intraclass coefficient and correlation was poor.
conclusionSa-cortisol in cosyntropin-test has high diagnostic accuracy in detecting adrenal insufficiency and is particularly useful in women on oral estrogens. An sa-cortisol ≥ 12.6 nmol/L assayed with liquid chromatography tandem mass spectrometry 60 minutes after 250 µg cosyntropin is normal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.